Basic fibroblast growth factor enhanced LAK cell cytotoxicities against human bladder neoplasm cells.
OBJECTIVE
To study the effects of basic fibroblast growth factor (bFGF) on the proliferation of lymphokine-activated killer (LAK) cells from patients with bladder cancer and LAK cells cytolysis against bladder tumor cells.


METHODS
LAK cell proliferation was assayed in the presence of various concentrations of bFGF combined with interleukin-2 (IL-2) by cell count. Cytotoxicity of LAK cells against bladder cancer cell line EJ cells and bladder tumor cells (BTC) from patients was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays.


RESULTS
The proliferation of peripheral blood monocytes (PBMC) was inhibited by bFGF 5 micrograms.L-1. bFGF did not affect the stimulation of LAK cells induced by IL-2. The LAK cell numbers in the combination of IL-2 with bFGF were not significantly different compared with that treated with IL-2 alone. bFGF enhanced cytotoxicity of LAK cells against bladder cancer cell line EJ cells or BTC, respectively.


CONCLUSIONS
Although the proliferation of PBMC was inhibited by bFGF, bFGF increased LAK cell cytotoxicity against bladder neoplasm cells.
Wang
Z P
ZP
Institute of Urology, 2nd Affiliated Hospital of Lanzhou Medical College, China.
Duan
G L
GL
Chen
Y R
YR
Qin
D S
DS
Liu
G D
GD
Niu
H G
HG
D002295:Carcinoma, Transitional Cell / Q000276:immunology* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D006801:Humans; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology* / Q000473:pathology; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000473:pathology
D016222:Fibroblast Growth Factor 2